A Phase 3 double‑blind trial published in The Lancet shows that adding the viral immunotherapy aglatimagene besadenovec to radiotherapy improves disease‑free survival for men with localized high‑risk prostate cancer.
A Phase 3 double‑blind trial published in The Lancet shows that adding the viral immunotherapy aglatimagene besadenovec to radiotherapy improves disease‑free survival for men with localized high‑risk prostate cancer.